Fenwick Represents Melinta Therapeutics in Acquisition of U.S. Rights to TOPROL-XL from New American Therapeutics

Fenwick represented Melinta Therapeutics, a company providing innovative therapies for acute and life-threatening illnesses, in its acquisition of the U.S. rights to TOPROL-XL (metoprolol succinate) and its Authorized Generic (AG) from New American Therapeutics, a pharmaceutical company.

More information can be obtained from Melinta Therapeutics’ announcement.

The Fenwick transaction team included corporate partners Ethan Skerry and Matt Rossiter and associate Jiarui Li; and technology transactions partner Jake Handy.